Supernus Pharmaceuticals Inc Asset Resilience Ratio
Supernus Pharmaceuticals Inc asset resilience ratio. Supernus Pharmaceuticals Inc (SUPN) has an Asset Resilience Ratio of 13.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Supernus Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Supernus Pharmaceuticals Inc (2008–2025)
Asset resilience ratio of Supernus Pharmaceuticals Inc from 2008 to 2025. This chart shows how Supernus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Supernus Pharmaceuticals Inc (SUPN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Supernus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Supernus Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $192.11 Million | 13.45% |
| Total Liquid Assets | $192.11 Million | 13.45% |
Asset Resilience Insights
- Moderate Liquidity: Supernus Pharmaceuticals Inc has 13.45% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Supernus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Supernus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Supernus Pharmaceuticals Inc Asset Resilience Ratio by Year (2008–2025)
Supernus Pharmaceuticals Inc asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Supernus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.41% | $180.22 Million | $1.45 Billion | -15.68pp |
| 2024-12-31 | 28.09% | $384.28 Million | $1.37 Billion | +14.02pp |
| 2023-12-31 | 14.07% | $179.82 Million | $1.28 Billion | -7.55pp |
| 2022-12-31 | 21.63% | $368.21 Million | $1.70 Billion | +13.56pp |
| 2021-12-31 | 8.07% | $136.25 Million | $1.69 Billion | -0.84pp |
| 2020-12-31 | 8.90% | $133.89 Million | $1.50 Billion | -5.38pp |
| 2019-12-31 | 14.28% | $165.69 Million | $1.16 Billion | -2.47pp |
| 2018-12-31 | 16.75% | $163.77 Million | $977.81 Million | +7.39pp |
| 2017-12-31 | 9.36% | $39.74 Million | $424.46 Million | +1.70pp |
| 2016-12-31 | 7.66% | $23.72 Million | $309.57 Million | -7.19pp |
| 2015-12-31 | 14.86% | $28.04 Million | $188.73 Million | -12.73pp |
| 2014-12-31 | 27.59% | $37.94 Million | $137.51 Million | -16.75pp |
| 2013-12-31 | 44.34% | $49.21 Million | $111.00 Million | -6.95pp |
| 2012-12-31 | 51.29% | $48.21 Million | $93.99 Million | +50.83pp |
| 2011-12-31 | 0.46% | $245.00K | $53.73 Million | -18.61pp |
| 2010-12-31 | 19.07% | $8.96 Million | $47.01 Million | -24.88pp |
| 2009-12-31 | 43.95% | $35.12 Million | $79.90 Million | +34.23pp |
| 2008-12-31 | 9.73% | $7.50 Million | $77.13 Million | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more